GRC 65327 / Glenmark - LARVOL DELTA

Discovery of GRC 65327, a best-in-class, selective and potent Cbl-b inhibitor for the treatment of advanced solid cancers (AACR 2025) - "Additionally, unlike a previous less-selective lead which exhibited RTK-mediated toxicities in various organs during exploratory tox study in rodents, GRC 65327 did not show adverse effects, highlighting its improved selectivity and safety profile. Based on these findings, a first-in-human clinical trial of GRC 65327 is scheduled to begin in advanced solid cancers."

IO biomarker • Metastases • Colon Cancer • Colorectal Cancer • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • IFNG • IL2 • NOTCH1

GRC 65327, a novel small molecule selective Cbl-b inhibitor for solid tumors (SITC 2024) - "Conclusions GRC 65327 is a novel, selective, orally active Cbl-b inhibitor that demonstrates good in vitro potency, in vivo efficacy with monotherapy, with potential to enhance checkpoint blocker-based immunotherapy regimens and acceptable safety profile in mice. IND enabling studies are underway."

Colon Cancer • Colorectal Cancer • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • CTLA4

IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer (GlobeNewswire) - "Ichnos Glenmark Innovation (IGI)...and Glenmark Pharmaceuticals Ltd., today announced a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH) in the United States. Under the CRADA, IGI and NCI will collaborate on evaluating IGI's proprietary Cbl/b small molecule, GRC 65327....In the research covered by the CRADA, NCI will first characterize and then test GRC 65327 in immune-competent models of triple-negative breast cancer (TNBC) with the intent of generating preclinical data to support a clinical trial in late-stage TNBC at NCI."

Licensing / partnership • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer